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Clinical and histopathological observations suggest that the pathogenesis of
cutaneous melanoma evolves through multiple stages . It has been proposed that
early stages are characterized by benign proliferation of melanocytic cells and
later stages by acquisition of competence for invasion and metastasis (1) . The
recognition that dysplastic nevi are a class of pigmented lesions with potential
for malignant change is consistent with the existence of a precursor step in the
development of melanoma (2) . Phenotypic markers that discriminate normal
melanocytes from melanoma cells would be particularly useful for dissecting
stages in melanocyte transformation . However, definitive criteria that distinguish
benign melanocytes from premalignant and malignant cells have not been estab-
lished .
In previous studies, we have used morphology, pigmentation, and expression
of cell surface and intracellularantigens to characterize the phenotype ofcultured
human melanocytes and melanomas (3, 4) . Serological typing has revealed that
antigens that are expressed on a subset of melanomas or melanocytes generally
are regulated by the melanocyte differentiation program (3, 4) . During these
investigations, an antigen system was recognized whose pattern of expression
was remarkable because it was not associated with the stage of melanocyte
differentiation, but appeared to be regulated with melanocyte transformation .
This antigen system was expressed by all cultured melanocytes but not by
melanomas . mAbs that react with this antigen bind to a 120AD cell surface
glycoprotein that has been identified as the adenosinedeaminase binding protein
(ADAbp) (5) . These studies indicate that cell surface expression of ADAbp is
downregulated and apparently extinguished during the process of melanocyte
transformation .
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ADENOSINE DEAMINASE EXPRESSION BY MELANOCYTES
Materials and Methods
Cell LinesandTissue Culture.
￿
Melanoma cell lines, cutaneousand choroidal melanocyte
and nevus cultures were derived by previously described techniques (6, 7). Cultures of
melanocytic cells were maintained in Eagle's MEM supplemented with 2 mM glutamine,
0.1 mM nonessential amino acids, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 10%
FCS (complete medium). Cells were passaged with trypsin 0.25% (wt/vol) and EDTA
0.02% (wt/vol). All nevus specimens were diagnosed by standard clinical and histological
criteria by the Department of Pathology, Memorial Sloan-Kettering Cancer Center. For
preparation ofmelanocyte cultures, connective tissue, deep dermis, and fat were dissected
from skin, nevus, or choroid. Fragments ofspecimens were incubated overnightin Eagle's
MEM with trypsin 0.25% at 4°C. Epidermis was separatedfrom dermis in skin specimens,
preparations were gently vortexed, and detached cells were grown in complete medium
supplemented with 10 ng/ml PMA (Consolidated Midland Corp., Brewster, NY) and 10`
M cholera toxin (Schwartz/Mann Biologicals, Orangeburg, NY) (melanocyte medium) (7),
except where noted. Dermal cells were plated for nevus specimens and epidermal cells
for cutaneous melanocyte cultures. For specific experiments, epidermal melanocytes were
established in complete medium containing melanocyte growth factors derived from cell
extracts of WI-38 fetal fibroblasts (McGF-W) or from the melanoma cell line SK-MEL-
131 (McGF-M) (8).
Serological Assays.
￿
mAbs S6, S23, and S27 are IgG1 mouse mAbs reacting with
different epitopes on ADAbp (5, 9, 10). mAbs were purified from ascites of hybridoma-
bearing mice by 45% ammonium-sulfate precipitation followed by chromatography
through DEAE-Sepharose (Pharmacia Fine Chemicals, Piscataway, NJ). Anti-mouse Ig
mixed hemadsorption assay was performed as described previously (11). Indicator cells
were prepared by conjugating purified rabbit anti-mouse y heavy chain (Dako Corp.,
Santa Barbara, CA) to human O+ red bloodcells with 0.01% (wt/vol) chromium chloride.
Assays were performed on cells grown in microtest plates (model 3040; Falcon Labware,
Oxnard, CA). Target cells plated 2-3 d previously were incubated with serially diluted
antibody for 1 h at room temperature. Target cells were washed and indicator cells were
added for 45 min. Titers were defined as antibody dilution giving 20% rosetted target
cells when evaluated by light microscopy. Indirect immunofluorescence assays were
performed in Falcon Labware (model 3040) plates (12). Cells were fixed in 3.7% formal-
dehyde for 10 min, washed with PBS, and incubated with goat anti-mouse Ig conjugated
to fluorescein (Cooper Biomedical, Inc., Malvern, PA) diluted 1/50 for 30 min. For
absorption tests (13), mAbS23 or S27 was initially titered against FS10 target melanocytes
and SK-RC-1 renal cancer cell lines, and a dilution that was two doubling dilutions below
the titer endpoint was used for absorption. Diluted mAb was incubated with packed
melanoma cells (1 .5:1 vol/vol) or renal cancer cell line SK-RC-1 (positive control) for 1 h.
Absorbing cells were centrifuged, and absorbed and unabsorbed mAb were tested for
reactivity against FS 10 melanocytes.
Immunohistological Staining. Frozen tissue sections 4-8 jum thick were cut using a
Bright OTF cryostat with a 530 microtome (Hacker Instruments, Inc., Fairfield, NJ). For
indirect immunofluorescence,cryostat-cut sections were fixedfor 10 min with 1% formalin
in PBS (pH 7.4). Tissue sections were washed, then incubatedwith primary antibody mAb
S27 at 20 ttg/ml for 1 h. All incubations were performed at room temperature in wet
chambers.
Sections were washed andincubated for45 min with secondaryfluoresceinatedantibody
(1 :40) (Cappel Laboratories, Cochranville, PA). Tissue sections were washed extensively
in PBS and wet mounted in 90% glycerol in PBS. The specimens were examined with a
fluorescence photomicroscope equipped with epifluorescence, using a 100 W mercury
lamp (Nikon Inc., Garden City, NY). For indirect immunoperoxidase (14), frozen sections
were treated for 10 min with 1% hydrogen peroxide in PBS to remove endogenous
peroxidase activity, incubated with 10% normal goat serum for 20 min, then with 20
Icg/ml mAbS27 overnight for 4°C. Secondary horseradish peroxidase-conjugated rabbit
anti-mouse Ig (Tago Inc., Burlingame, CA) was incubated for 45 min. For the final
reaction, diaminobenzidine 0.005% (wt/vol) (Sigma Chemical Co., St. Louis, MO) wasHOUGHTON ET AL.
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dissolved with 100 kl of 0.3% hydrogen peroxide. Frozen normal kidney tissue sections
served as positive controls for each experiment. Negative controls included 20 Fcg/ml of
mouse IgGI mAb S1 .
Radioimmunoprecipitation.
￿
Cell labeling, immunoprecipitation, and gel electrophoresis
were carried out as previously described (15). Cells were labeled with [5H]glucosamine
(New England Nuclear, Boston, MA) over 72 h in glucose-free Eagle's MEM containing
7.5% dialyzed FCS, and cell extracts were prepared in NP-40 0.5% (vol/vol), 10 mM Tris-
HCI, pH 7 .4, and 150 mM NaCl. Lysates were radioimmunoprecipitated with mAb
followed by 5 ng/ml protein A-Sepharose (Pharmacia Fine Chemicals), then reduced with
dithiothreitol (Boehringer-Mannheim, Indianapolis, IN); immunoprecipitates were re-
solved by SDS-PAGE.
Binding Assays with Radiolabeled Antibody and Adenosine Deaminase.
￿
Bovine intestine
adenosine deaminase was purchased from Calbiochem-Behring Corp. (La Jolla, CA).
Adenosine deaminase was further purified by fast-performance liquid chromatography
(Pharmacia Fine Chemicals) with a Mono Q anion exchange column . The column was
eluted with a salt gradient from 5 mM to 1 M NaCl in MES buffer (2-[N-morpholino]
ethane-sulfonic acid) (Sigma Chemical Co.), 0 .05 M, pH 6. Purified adenosine deaminase
gave a single band of ^-38 kD on SDS-PAGE stained by Coomassie blue. Purified adenosine
deaminase and purified mAbs S23 and S27 were labeled with `251 (New England Nuclear)
by the chloramine T method. Labeled protein was separated by a G50 fine Sephadex
(Pharmacia Fine Chemicals) column. Radiolabeled adenosine deaminase was additionally
dialyzed against PBS. The specific activity was 0.5-1 .0 ACi/Pg for adenosine deaminase
(>80% binding by absorption tests with cultured melanocytes) and 1-5 ACl/Ag for mAbs
(>80% immunoreactive by absorption tests). SDS-PAGE revealed a single protein band
of ' 25I-labeled adenosine deaminase (^-38 kD) and ofmAbs (^-160 kD) under nonreducing
conditions. Binding assays and RIAs were performed by incubating 105 target cells with
radiolabeled adenosine deaminase or mAb in the presence or absence of >10-fold excess
cold adenosine deaminase or mAb, respectively, for 2 h at 4°C. Cells were pelleted for
30 s, washed, and counted for cell number and for radioactivity in a gamma counter.
Specific binding was determined from the following calculation : Specific binding = (bound
radiolabeled protein in the absence of cold protein) - (bound radiolabeled protein in the
absence of excess cold protein). Nonspecific binding was <10% of total bound protein .
Binding curves were determined by third order polynomial smoothing using Statgraphics
software package (STSC, Inc., Rockville, MD).
Infection ofMelanocyteswith Murine Sarcoma Virus.
￿
Viral stocks were isolated from NIH
3T3 nonproducer clones infected with Kirsten murine sarcoma virus (Ki-MSV) or Harvey
murine sarcoma virus (Ha-MSV) and superinfected with 4070A amphotrophic murine
leukemia virus (MuLV) (16). Ki-MSV and Ha-MSV pseudotypes were harvested from 24-
h cell-free supernatants and stored at -70°C. For infection, 105 melanocytes were treated
for 60 min with DEAE/dextran (25 mg/ml), washed, and incubated with virus at a
multiplicity ofinfection of 1 PFU/cell. Transforming activity of virus produced by infected
melanocytes was determined by focus assays on NIH 3T3 cells (17). Focus forming units
per milliliter of supernatant fluid were 3 x 104 for Ha-MSV and 3 x 105 for Ki-MSV
(16). Cloning efficiency was determined by plating 105 cells in soft agar (0 .75% bottom
layer and 0 .3% top layer) and scoring colonies of >50 cells at 2-3 wk.
In Vitro Transformation of Melanocytes.
￿
Two human newborn foreskin melanocyte
cultures, FS1190 and FSIOW, were transformed according to the following procedure.
Before transformation, cell strains were maintained in melanocyte medium (7) as described
above and were passaged at a regular interval of 3 weeks and at a ratio of 1 :3. For
induction of transformation, cell lines FS1190, passage 15, and FS10W, passage 29, were
grown in complete medium containing PMA, cholera toxin and isobutylmethylxanthine
(IBMX) 10-5 M (18). This supplemented medium induced rapid proliferation of melano-
cytes. Cultures were then passaged every 3 wk, and during the next 1-2 mo colonies of
morphologically altered cells were observed. After 2 mo in PMA/cholera toxin/IBMX-
supplemented medium, colonies were selected that grew in complete medium without
PMA (PMA is the crucial mitogenic factor in melanocyte medium) (7). After initial200 ADENOSINE DEAMINASE EXPRESSION BY MELANOCYTES
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FIGURE 1.
￿
Serological typing for expression of ADAbp by mAb S27 with anti-mouse Ig
mixed hemadsorption assays of cultured melanocytes (51 cell lines), nevi (5), and melanomas
(102). Each circle representsa test with an individual cell line.
selection of transformed colonies, cells were grown in complete medium without any
addition of PMA, cholera toxin, or IBMX. When parental cell lines FS 1190 and FS IOW
were maintained in melanocyte medium in the absence of IBMX, no transformed colonies
were observed .
Adenosine Deaminase Binding Protein Is Expressed by Cultured Melanocytes but
not by Melanomas. We have previously reported results of serological typing of
cultured melanocytes and melanomas using a large panel of mouse mAbs (3, 4).
Three categories of antigens have been distinguished: (a) antigens expressed by
fetal, newborn, and adult melanocytes and by a subset of melanomas at inter-
mediate or late stages of melanocyte differentiation (7 antigen systems); (b)
antigens expressed by a subset of melanoma cell lines corresponding to early or
intermediate stages of melanocyte differentiation (8 antigens); and (c) antigens
widely expressed by cultured melanomas and melanocytes (82 antigens). We now
describe a fourth category of melanocyte antigen, the ADAbp, that is expressed
by cultured melanocytes but not by melanomas.
Fig. I shows the results of serological typing for expression of ADAbp on a
panel of cultured melanocytes and melanomas using mAb S27. ADAbp was
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FIGURE 2 .
￿
Serological typing for ADAbp expression by mAb S27 with anti-mouse Ig mixed
hemadsorption assays. (A) Typing of three melanocyte (FS125, AS801, and OC1) and three
melanoma (SK-MEL-28, SK-MEL-31, and SK-MEL-190) cell lines. (B) Typing of melanocyte
cell line FS 118 established in PMA or in melanocyte growth factors derived from WI-38 fetal
fibroblast cell line (McGF-W), and cell line FS120 established in melanocyte growth factors
derived from the melanoma cell line SK-MEL-131 (McGF-M) (see reference 8). (C) Typing of
melanocytes and melanoma cells shortly after explantation into tissue culture; melanocyte
culture FWS118 was typed 4 d after explantation and melanoma culture SK-MEL-146 was
typed 2 d and 5 d after explantation. (D) Typing of melanocytic cells from a giant congenital
nevus(CN-1) and dysplastic nevi (DN-1 and DN-2). (E) Typing ofmelanocyte cell line FS1346
infected with Ki-MSV (FS1346-Ki), Ha-MSV (FS1346-Ha), or uninfected cells [FS1346(P)].
(F) Typing of untransformed (FS1190 Control) and transformed (FS1190 Transformed)
melanocyte cell line FS1190.
detected on the cell surface of 51 melanocyte cultures derived from fetal,
newborn, and adult skin and adult choroid. Identical results were observed in
assays using mAbs S6 and S23, which detect different epitopes on the ADAbp
molecule. Fig. 2A demonstrates representative mixed hemadsorption assays for
binding of mAb S27 to cultured melanocytes. In contrast to melanocytes, ADAbp
was not detected on the cell surface of 102 melanoma cell lines derived from202
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either primary or metastatic lesions (Figs. 1 and 2A). Lack of binding of mAbs
S23 and S27 by cultured melanomas was confirmed by binding assays with ' 251-
labeled mAbs (see below). Absorption tests, a sensitive serological assay for cell
surface antigen expression, failed to reveal any ADAbp expression by melanoma
cells. Melanoma cell lines SK-MEL-23, SK-MEL-30, and SK-MEL-37 did not
absorb any reactivity of mAbs S23 or S27 against the FS10 melanocyte cell line
or against the renal carcinoma cell line SK-RC-1.
Melanoma cell lines corresponding to early, intermediate, and late stages of
melanocyte differentiation, were ADAbp-, whereas cultured melanocytes (at
intermediate and late stages of differentiation) were uniformly ADAbp+. Thus,
stage of differentiation did notappear to influence the level of ADAbp expression
by melanocytes.
Melanocytes, unlike cultured melanoma cells, require exogenous growth fac-
tors to proliferate in tissue culture. To demonstrate that ADAbp expression was
not simply the result of induction by exogenous growth factors, melanocytes
were established under different growth conditions and tested for expression of
ADAbp (Fig. 2B). ADAbp was equally expressed by melanocytes established in :
(a) the phorbol ester PMA with or without cholera toxin, (b) cholera toxin alone
(these cultures contained a mixture of keratinocytes and melanocytes, but mela-
nocytes were easily distinguished by their morphology and pigmentation), (c)
melanocyte growth factor derived from the fetal fibroblast cell line WI-38, and
(d) melanocyte growth factor derived from the melanoma cell line SK-MEL-131 .
Conversely, 18 melanoma cell lines grown in PMA with or without cholera toxin
forperiodsof 1-3 mo remained ADAbp (data not shown) . Expression of ADAbp
by melanocytes and lack of expression by melanomas were not related to rate of
growth (doubling times ranged from 48 h to >120 h for melanocyte cultures
and 20 h to >120 h for melanoma cultures) or degree of confluency in tissue
culture. Melanocytes cultured in complete medium without growth factors stop
proliferating within 5-7 d (7). No change in ADAbp expression, determined by
titers of mAbs S6, S23, and S27, was observed 5 and 7 d after removal of the
growth factors PMA and cholera toxin from melanocyte cultures, suggesting
that ADAbp expression was not strictly related to cell proliferation .
ADAbp was detected on the cell surface of newborn foreskin melanocytes by
mixed hemadsorption assays as early as 4 d after explantation into tissue culture
(Fig. 2C). In these assays, pigmented, bipolar spindle-shaped melanocytes could
easily be distinguished from other cell types, i.e., fibroblasts and keratinocytes,
in the culture. Freshly cultured melanocytes, at day 4 after explant, were
observed to express lower levels of ADAbp than cultures at day 8 (Fig. 2C). This
low expression possibly is related to preparation of epidermal specimens in
trypsin and EDTA for 18-24 h before placement in culture; cell surface ADAbp
is removed by trypsin treatment (9). No ADAbp expression was detected in
freshly explanted melanoma cultures as early as day 2 in culture (Fig. 2C).
ADAbp synthesis by melanocyte cultures was confirmed by radioimmunopre-
cipitation experiments using whole cell lysates of melanocytes metabolically
labeled with [sH]glucosamine (Fig. 3) . The molecular size of ADAbp on mela-
nocytes (120,000 mol wt) was identical to previously characterized ADAbp
expressed by control renal cell carcinoma cell line SK-RC-1 (5, 9). ADAbpO
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FIGURE 3 . Immunoprecipitation
ofADAbp from melanocyte cell line
FS 101, renal cell carcinomaSK-RC-
I (positive control) and melanomas
SK-MEL-30 and SK-MEL-37 . Cells
were metabolically labeled with
[9H]glucosamine and cell lysates
were immunoprecipitated with mAb
S23 (lanes 1, 3, 5, and 7) or mAb
S27 (lanes 2, 4, 6, and 8) .
FIGURE 4. Specific binding of 121I-labeled bovine adenosine de-
aminase per 105 cells to melano-
cyte cell line FS121 (a) andmela-
noma SK-MEL-23 (0).
expression was not detected in metabolically labeled melanoma cells even after
extended exposure of autoradiographs (data not shown), demonstrating that
undetectable cell surface expression by melanoma cells was not accompanied by
discernible ADAbp in cytoplasmic compartments .
Studies with Radiolabeled Bovine Adenosine Deaminase and Anti-ADAbp
mAbs. To confirm that ADAbp detected by serological techniques actually
corresponded to binding sites for adenosine deaminase, '25I-labeled bovine
adenosine deaminase was tested for specific binding to cultured melanocytes and
melanomas . Fig . 4 demonstrates an experiment showing saturable binding of204
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radiolabeled adenosine deaminase to the melanocyte cell line FS 121 but no
specific binding to the melanoma cell line SK-MEL-23. From this experiment it
was estimated that FS121 melanocytes expressed a mean of 3.8 X 105 ADAbp
molecules per cell. These calculations were based on one adenosine deaminase
binding site per ADAbp molecule (19). In adenosine deaminase binding assays
with three other newborn foreskin melanocyte cultures, FS 101, FS 123, and
FS1404, 1 .6 X 105, 3.6 X 105, and 9.2 X 10' mean binding sites per cell were
detected, respectively. No specific binding of bovine adenosine deaminase was
observed to the melanoma cell lines SK-MEL-13, SK-MEL-30, SK-MEL-31, SK-
MEL-37, and SK-MEL-93.
Experiments with 1251-labeled mAbs S23 and S27 gave a similar range for
mean number of cell surface ADAbp molecules per melanocyte. Newborn
foreskin melanocytes FS 101, FS 118, and FS 120 had a mean of 1.4 x 105, 2.4 x
105, and 5.8 X 10' binding sitesper cell, respectively. These calculations assumed
that each ADAbp has one binding site for each mAb and that each divalent IgG
mAb can bind to two ADAbp molecules at saturation . Radiolabeled mAbs S23
and S27 showed no specific binding to melanoma cell lines SK-MEL-23, SK-
MEL-31, and SK-MEL-37. It has been previously demonstrated that mAb S27
does not inhibit binding of adenosine deaminase to ADAbp (5), and therefore
inhibition experiments were not performed.
Cultured Congenital and Dysplastic Nevi Express Little or No Adenosine Deaminase
Binding Protein. Nevi, which are benign collections of melanocytic cells in the
skin, can contain morphologically normal or dysplastic-appearing cells. Dysplastic
and giant congenital nevi are potentially premalignant lesions and have been
observed to evolve into primary melanoma (2). Cultures of melanocytes derived
from two dysplastic nevi and three giant congenital nevi were assayed for
expression of ADAbp. Care was taken during preparation of nevus cultures to
select dermal and epidermal areas within the specimen that contained nevus
cells. Pigmented cells derived from giant congenital and dysplastic nevi expressed
little or no ADAbp, with the exception of melanocytes derived from one
congenital nevus specimen (Figs. 1 and 2D). The decrease or loss of ADAbp
expression was the only phenotypic trait that distinguished pigmented cells of
dysplastic and congenital nevi from cultured melanocytes derived from normal
skin. Otherwise, cultures from congenital and dysplastic nevi and normal skin
were phenotypically comparable: cells remained dependent on growth factors
for proliferation and expressed intermediate and late markers of melanocyte
differentiation but not early markers; notably, melanocytes cultured from dys-
plastic and congenital nevi did not express class II major histocompatibility (Ia)
antigens or epidermal growth factor receptor, which are traits expressed by a
subset of melanomas (4).
Immunohistological Studies with mAb S27 in Formaldehyde-fixed Frozen Tis-
sues. A limited panel of formaldehyde-fixed, frozen sections of normal skin,
junctional nevi, dysplastic nevi, and primary and metastatic melanomas was
examined for staining with mAb S27 (20 ug/ml) by indirect immunofluorescence
and immunoperoxidase techniques . (Fig. 5). There was detectable staining by
mAb S27 of normal epidermal melanocytes in most specimens and of dermal
fibroblasts in all specimens (Figs. 5 and 6). Staining of normal fibroblasts byHOUGHTON ET AL.
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FIGURE 5.
￿
Typing for ADAbp expression with mAb S27 on fro-
zen tissue sections by immunofluorescence and immunoperoxidase
techniques. Tissues were fixed with 3.7% formaldehyde. (") Posi-
tive staining; (O) no staining.
mAbs against ADAbp hasbeen reported previously (10). Nostaining ofepidermal
melanocytes was observed in one specimen ofpalm skin (Fig. 5). mAbS27 stained
pigmented cells in twojunctional nevi with a heterogeneous pattern (Figs. 5 and
6). No staining of two dysplastic nevi or a small panel of primary and metastatic
melanomas was detected (Figs. 5 and 6). It was observed that normal appearing
melanocytes inthe epidermis at theborders ofdysplastic nevi, primary melanoma
specimens, and cutaneous metastases were stainedwith mAb 27 (data not shown).
These findings suggest that normal epidermal melanocytes in proximity to
dysplastic nevi or primary melanomas have a normal phenotype and are not part
ofa field ofpremalignant or malignant cells.
Cultured Melanocytes Infected by Ha-MSV/Ki-MSV Continue to Express
ADAbp. The relationship of malignant transformation and regulation of AD-
Abp on melanocytic cells was investigated further by infecting melanocytes with
transforming amphotropic pseudotypes of Ha-MSV or Ki-MSV. Ha-MSV and
Ki-MSV contain activated oncogenes of the ras family. In a previous report we
have shown that infection of normal cultured human melanocytes with Ki-MSV
or Ha-MSV, but not control amphotropic MuLV helper virus, led to induction
of certain phenotypic traits of melanoma cells (16), including: (a) morphologic
alterations characterized by clustering and piling up of cells, (b) increased growth
rate and saturation density, (c) anchorage-independent growth with cloning
frequencies in soft agar ranging from 0.04-0.1 %, (d) induction ofclass II major
histocompatibility (Ia) antigens, and (e) augmentation of cell surface expression
of the disialoganglioside GD3 (16). Expression of la antigens and prominent
expression of GD3 ganglioside are characteristics of melanoma cells. Despite
these changes, melanocytes expressing activated ras remained dependent on
exogenous growth factors for proliferation and were diploid at early passage
(with some hyperdiploid cells at later passages), without any detectable chromo-
somal alterations or rearrangements. Infection with Ki-MSV and Ha-MSV did
not induce any detectable change in the expression of ADAbp by melanocytes
(16) (Fig. 2E). These results indicate that downregulation of ADAbp expression
is not tightly regulated with other ras-induced transformation traits in melano-
cytes.
Loss of Expression of Adenosine Deaminase BindingProtein by Melanocytes Trans-
formed In Vitro. Melanocytes and other normal human cells have been difficult
to completely transform by a single oncogene as the transforming agent. Al-
though activated ras expression in melanocytes was able to induce certain
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FIGURE 6 . Immunofluorescence staining by
mAbS27 offrozen tissue sections fixed with 3.7
formaldehyde. Magnification x 220 . (A) Normal
skin ; white arrow points to positive staining of
normal epidermal melanocyte . (B) functional ne-
vus; white arrows point to heterogeneous staining
of junctional nevus . (C) Metastatic melanoma;
there is no staining of a cutaneous metastatic
melanoma lesion .
characteristics of transformed cells (16), loss of ADAbp expression was not
observed . During investigations ofconditions that control growth of melanocytes,
a novel system to transform human melanocytes was found (Eisinger, M. E., O .
Marko, A. N. Houghton, manuscript in preparation) . Transformed colonieswere
observed in rapidly dividing cultures of two independent melanocyte cell lines,
FS1190 and FS10W, derived from newborn foreskin . To elicit rapidly prolifer-
ating cells, cultures were grown in PMA, cholera toxin, and IBMX (18), and
transformed-appearing colonies appeared after 1-2 mo . Transformed coloniesHOUGHTON ET AL. 207
had the following characteristics consistent with malignancy: (a) growth in
complete medium without addition of exogenous growth factors, (b) spindle and
polygonal-shaped cells with nuclear atypia and a high nuclear/cytoplasmic ratio,
(c)high saturation density, (d) formation ofcolonies in softagar,and(e)aneuploid
karyotype. On the other hand, the parental newborn foreskin melanocyte cell
lines FS1190 and FSIOW were dependent on exogenous factors for growth, had
a dendritic, bipolar-spindle morphology, grew at a low saturation density, were
unable to grow in soft agar, and had a diploid karyotype. Transformation of
FS1190 and FS10W cells was associated with loss of detectable ADAbp expres-
sion. Parental FS1190 and FSIOW cultures expressed levels ofADAbp that were
typical of other melanocyte cultures but transformants of FS1190 and FS1OW
were ADAbp- (Fig. 2F). This transformation system confirms that ADAbp
expression can be regulated during the process of melanocyte transformation.
Discussion
A constellation ofphenotypic traits distinguishes transformed cells from their
normal cell counterparts. Malignant cells characteristically acquire an altered
morphologyandappearance, grow in ananchorage-independent fashion, require
lower amounts of exogenous growth factors, and have an abnormal karyotype.
Despite these profound alterations, analysis of tumor cells has demonstrated that
malignant transformation generates mainly quantitative changes in expression of
cell components (i.e., increase or decrease) or modification of existing compo-
nents (e.g., posttranslational modification) rather than qualitative changes (i.e.,
presence or absence) (20). The subtle nature of critical phenotypic alterations is
demonstrated in certain cell systems where regulation of a single protein can
lead to transformation (21, 22). In our studies ofdeterminants detected by mAbs
S6, S23, and S27, ADAbp was strongly expressed on melanocytes but was not
detected on melanoma cells. These findings suggest that expression of ADAbp
may differ qualitatively between melanocytes and melanoma cells. However, this
presumption is limited by the sensitivity and specificity of the assays used to
measure ADAbp, and therefore it is possible that small numbers of ADAbp
molecules on melanoma cells are not detected or that only some determinants
on the ADAbp molecule are regulated during transformation.
Lack of staining of melanocytes in occasional skin specimens could be related
to an ADAbp phenotype (for instance in palm skin that may contain hyperpro-
liferative epidermal cells) or to insufficient sensitivity of immunostaining tech-
niques. In tests against cultured melanocytes fixed with 3.7% formaldehyde,
mAb S27 gave only weak to moderate staining by indirect immunofluorescence
techniques (titers of 1/200 to 1/3,200), indicating that immunostaining tech-
niques were not nearly as sensitive as mixed hemadsorption assays (titers 1/105
to 1/106) to detect ADAbp expression. In addition, epidermal melanocytes can
be difficult to evaluate by immunostaining methods because they comprise only
a small proportion of cells in the basal layer of the epidermis, they have
endogenous peroxidase activity that can interfere with peroxidase-mediated
staining, and they have pigment that can quench immunofluorescence staining.
Clark and coworkers (1) have proposed five "lesional steps" in the progression
from melanocyte to melanoma: (a) pigmented cells that are regulated and208
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restrained byadifferentiation program, (b) dysplastic pigmented cells, (c) primary
melanoma cells without competence for metastases, (d) primary melanoma cells
with competence for metastases, and (e) metastatic melanoma cells. In relation
to this scheme, normal melanocytes were ADAbp+, dysplastic nevi expressed
little or no ADAbp, and primary and metastatic melanoma cells were ADAbp-.
These data suggest that ADAbp expression decreases at a relatively early stage
in the pathogenesis of melanoma, coinciding with the appearance of cytologic
atypic (dysplastic nevi) and before acquisition of autonomous growth and inva-
siveness (primary melanoma). Studies ofmelanocyte transformation using culture
systems also suggest an association between genetic alterations and ADAbp
expression . Analysis ofcultured melanocyte cells that corresponded to presumed
early stages of transformation (e.g., melanocytes expressing activated ras genes
and cells derived from dysplastic nevi) showed that downregulation of ADAbp
on melanocytes is not coregulated with certain growth-related traits ofmalignant
melanocytes, specifically anchorage-independent growth or growth factor-inde-
pendent proliferation. One possibility is that chromosomal instability is closely
linked to loss of ADAbp expression, particularly since karyotypic abnormalities
can be observed in some melanocytes from dysplastic nevi and in most primary
and metastatic melanoma cells (23, 24). Further in vitro studies to dissect stages
of melanocyte transformation will be necessary to test this possibility.
Other markers have been proposed to distinguish "lesional steps." Certain
phenotypic traits of melanocyte cells derived from normal skin, nevi, primary
melanoma, and metastases have been examined in detail by Herlyn et al. (25,
26) according to Clark's model of tumor progression (1). Substantial alteration
in ganglioside pattern and changes in expression of several antigens have been
found that distinguish melanocytes derived from different lesional steps. Immu-
nohistological techniques also have been used to describe a number of antigens
that distinguish melanomas from benign nevi (27-32). According to serological
specificity and molecular size, none of these antigens appear to correspond to
ADAbp.
ADAbp is expressed by other cell lineages in addition to melanocytes (10, 33,
34). A relationship between ADAbp expression and malignancy was first sug-
gested in studiesevaluating isoenzyme expression in normal and malignant tissues
(35). Decreases in ADAbp expression have been described in certain epithelial
cancers including colon and kidney carcinomas, and in virally transformed
fibroblasts (36-38). In the case ofcolon carcinomas, more detailed studies have
demonstrated both increased and decreased ADAbp expression in tumors com-
pared to normal colon mucosa (39-40). Immunohistological studies have shown
a correlation between increased ADAbp expression and differentiation state of
the tumor, suggesting that ADAbp is regulated as part of the differentiation
program of normal colon epithelium (39-40). However, within the melanocyte
lineage there was no apparent association between ADAbp expression and stage
of differentiation, consistent with the notion that ADAbp is expressed in the
normal melanocyte lineage but is specifically downregulated as part of a trans-
formation process. Expression of ADAbp can be contrasted with another set of
cell surface glycoproteins, la antigens, that are regulated by both transformation
and differentiation in melanocytes (4). We have found that la can be induced inHOUGHTON ET AL.
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melanocytes by viral ras gene products (16) and by melanocyte transformation
in vitro (Eisinger, M., L.J. Davis, and A. N. Houghton, unpublished observation)
and additionally that la can be regulated in cloned melanoma cell lines as part
of the melanocyte differentiation program (4).
Although ADAbp is known to bind adenosine deaminase (19), the function of
the binding protein itself is unknown. Adenosine deaminase catalyzes irreversible
deamination of adenosine to inosine and deoxyadenosine to deoxyinosine, and
binding to ADAbp does not seem to affect the activity of the enzyme (19, 33).
Unlike many cell surface receptors, evidence suggests that ADAbp does not
transport adenosine deaminase into cells but rather holds the enzyme at the cell
surface (41). One possibility is that loss of ADAbp could allow transformed
melanocytes to become susceptible to inductive effects of adenosine. Studies to
evaluate the possible role of adenosine on melanocytes' growth and differentia-
tion are underway. ADAbp could influence intracellular events, for instance
DNA replication or repair through effects on purine metabolism. According to
either of these possibilities, the loss of expression of ADAbp by melanoma cells
would directly influence the transformed phenotype, perhaps through regulation
of cell growth or error-prone synthesis and repair of DNA. On the other hand,
loss ofADAbpexpression may be a secondary event, and therefore a consequence
of changes in growth or differentiation of malignant cells. In either case, well-
defined markers that distinguish melanocytes from melanoma cells will facilitate
investigations of melanocyte transformation in vitro and in vivo.
Summary
It has been proposed that the pathogenesis of melanoma proceeds through
multiple stages, ranging from benign proliferation of melanocytic cells to acqui-
sition of the capacity to invade tissues and metastasize. During investigations of
cell surface antigens expressed by melanocytes and melanoma, we identified an
antigen system that was expressed by cultured normal melanocytes but not by
melanoma cell lines. mAbs against this antigen detected a 120-kD cell surface
glycoprotein on melanocytes. This molecule had been identified previously as
the binding protein for adenosine deaminase (ADAbp). ADAbp was expressed
by 51 melanocyte cell lines derived from normal fetal, newborn, and adult skin
and adult choroid, but not by 102 melanoma cell lines derived from primary
and metastatic lesions. Studies with radiolabeled bovine adenosine deaminase
confirmed that melanocytes expressed binding sites for adenosine deaminase,
but no binding sites were detected on cultured melanoma cells. Further studies
showed that ADAbp+ melanocytes became ADAbp- upon malignant transfor-
mation in vitro. Immunohistochemical studies on a panel of frozen tissues
demonstrated reactivity of anti-ADAbp mAbs with epidermal melanocytes and
benign junctional nevi, but not with potentially premalignant dysplastic nevi or
primary/metastatic melanoma lesions. These studies demonstrate that ADAbp
expression is lost with malignant transformation of melanocytes, presumably at
an early stage in the transformation process.
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